Heart Failure with Reduced EF — Guideline-Directed Therapy

Key Points

• HFrEF is generally LVEF 40% or lower in the current AHA/ACC/HFSA framework.
• Foundational therapy consists of ARNI or other RAS inhibition, evidence-based beta blocker, MRA, and SGLT2 inhibitor.
• Start the four classes early at tolerated doses instead of waiting to fully titrate each drug sequentially.
• SGLT2 inhibitors reduce HF events regardless of diabetes status.
• Loop diuretics treat congestion but do not replace mortality-reducing GDMT.
• Continue HFrEF therapy when EF improves unless a specific contraindication develops.
• Monitor potassium, creatinine, blood pressure, heart rate, and volume status during initiation and titration.
• Refer early for advanced-HF evaluation when recurrent decompensation or intolerance suggests progression.

Algorithm

1. Confirm HFrEF by echocardiography and evaluate ischemic, valvular, rhythm, toxic, genetic, and systemic causes.
2. Assess congestion, blood pressure, heart rate, renal function, potassium, iron status, and current medications.
3. Initiate or optimize an ARNI or alternative RAS inhibitor, evidence-based beta blocker, MRA, and SGLT2 inhibitor as tolerated.
4. Use loop diuretic therapy to achieve and maintain euvolemia.
5. Recheck laboratory values and symptoms after each meaningful medication change and titrate toward evidence-based doses when feasible.
6. Assess indications for hydralazine-isosorbide dinitrate, ivabradine, IV iron, anticoagulation for AF, or other adjuncts.
7. Reassess EF after adequate GDMT when device therapy may be indicated and evaluate ICD or CRT criteria.
8. Refer to an advanced HF team for recurrent admissions, persistent severe symptoms, shock, inotrope dependence, or progressive end-organ dysfunction.

Clinical Synopsis & Reasoning

HFrEF is a clinical syndrome of symptoms and signs caused by structural or functional cardiac disease with reduced left ventricular systolic function. Typical symptoms include exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, edema, fatigue, and exercise intolerance. Evaluation should confirm LVEF, establish etiology, quantify congestion, identify reversible contributors, and define comorbidities that change treatment. Ischemic heart disease, prior myocardial infarction, hypertension, valvular disease, toxic exposures, myocarditis, genetic cardiomyopathy, tachyarrhythmia, and endocrine disease are important causes. A transthoracic echocardiogram is central to diagnosis and should document EF, ventricular dimensions, RV function, valve disease, and filling-pressure clues. BNP or NT-proBNP supports diagnosis when symptoms are nonspecific and has prognostic value, but levels are influenced by age, renal function, obesity, and atrial fibrillation. Evaluate iron status, renal function, potassium, blood pressure, diabetes, rhythm, and coronary disease. Patients whose EF improves above 40% after treatment are classified as HF with improved EF and should generally continue HFrEF therapy because withdrawal can lead to relapse. Distinguish chronic stable HFrEF from acute decompensation, because some medications can be initiated or continued in the hospital but hemodynamic instability, shock, severe AKI, or hyperkalemia may require temporary adjustment.

Treatment Strategy & Disposition

The four foundational HFrEF therapies should be started at low doses and brought on board early rather than waiting months to maximize one class before beginning the next. Sacubitril-valsartan is the preferred renin-angiotensin system inhibitor for symptomatic chronic HFrEF when tolerated; ACE inhibitors or ARBs remain alternatives when ARNI use is not feasible. Use an evidence-based beta blocker, specifically carvedilol, metoprolol succinate, or bisoprolol. Add a mineralocorticoid receptor antagonist such as spironolactone or eplerenone when renal function and potassium permit. Add an SGLT2 inhibitor such as dapagliflozin or empagliflozin regardless of diabetes status. Loop diuretics relieve congestion and should be titrated to maintain euvolemia, but they are not a substitute for disease-modifying therapy. Consider hydralazine-isosorbide dinitrate in self-identified Black patients with persistent symptomatic HFrEF despite optimal therapy and in patients unable to use renin-angiotensin inhibition. Ivabradine, digoxin, vericiguat, iron replacement, CRT, ICD therapy, revascularization, and advanced heart-failure therapies apply to selected patients. Titrate with close monitoring of blood pressure, heart rate, renal function, potassium, symptoms, and volume status. Refer patients with persistent NYHA III to IV symptoms, recurrent admissions, escalating diuretic need, inotrope dependence, progressive renal or hepatic dysfunction, or intolerance of foundational therapy to an advanced HF team.

Epidemiology / Risk Factors

• Ischemic heart disease and hypertension are major causes of HFrEF, but nonischemic and genetic cardiomyopathies are increasingly recognized.
• Diabetes, CKD, AF, obesity, sleep apnea, and iron deficiency commonly coexist and influence outcomes.
• Repeated HF hospitalization is a marker of disease progression and high short-term risk.
• Patients with improved EF remain biologically at risk for relapse despite apparent recovery.
• Access to and persistence with GDMT are major determinants of population-level outcomes.

Investigations

Core GDMT Components

Pharmacology

Prognosis / Complications

• The four foundational therapies substantially reduce death and HF hospitalization when tolerated and continued.
• Persistent congestion at discharge predicts early readmission and mortality.
• Improving EF generally improves prognosis but does not eliminate relapse risk.
• Sudden arrhythmic death and progressive pump failure remain major causes of mortality in advanced HFrEF.
• Early advanced-HF referral can preserve options for LVAD or transplantation before irreversible end-organ dysfunction develops.

Patient Education / Counseling

• Explain the purpose of each foundational medication, including drugs that are prescribed for heart failure even when blood pressure or diabetes are not the primary problem.
• Teach daily symptom and weight awareness and provide a clinician-specific plan for worsening edema or dyspnea.
• Avoid NSAIDs unless specifically advised and review sodium, alcohol, smoking, and fluid guidance individually.
• Seek urgent care for severe breathlessness at rest, syncope, chest pain, rapidly progressive swelling, or confusion.
• Keep laboratory follow-up after medication changes because potassium and kidney function can change before symptoms appear.

Notes

The practical goal is rapid, safe implementation of all four foundational therapies. Waiting several months to maximize one medication before starting the others delays benefit because each class works through a different pathway and can improve outcomes within weeks. Titration should be individualized rather than abandoned when low blood pressure or kidney dysfunction appears. First determine whether the patient is congested, dehydrated, over-diuresed, or taking unnecessary blood-pressure-lowering medication. Many patients tolerate lower doses of all four classes better than a high dose of only one or two. Continue surveillance after EF improves because withdrawal of therapy can lead to recurrent systolic dysfunction.

Exhibits

References

1. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — Link